0001750284-20-000002.txt : 20200623 0001750284-20-000002.hdr.sgml : 20200623 20200623130525 ACCESSION NUMBER: 0001750284-20-000002 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200623 DATE AS OF CHANGE: 20200623 EFFECTIVENESS DATE: 20200623 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001750284 IRS NUMBER: 300409740 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-363815 FILM NUMBER: 20981365 BUSINESS ADDRESS: STREET 1: 665 3RD STREET SUITE 250 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: 4157428265 MAIL ADDRESS: STREET 1: 665 3RD STREET SUITE 250 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 D/A 1 primary_doc.xml X0708 D/A LIVE 0001750284 Olema Pharmaceuticals, Inc. 665 3RD STREET SUITE 250 SAN FRANCISCO CA CALIFORNIA 94107 4157428265 DELAWARE CombiThera, Inc. None Corporation true Cyrus Harmon 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Executive Officer Director Frank McCormick 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Director Andrew Rappaport 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Director Gorjan Hrustanovic 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Director Graham Walmsley 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Director Peter Kushner 665 3rd Street,Suite 250 San Francisco CA CALIFORNIA 94107 Executive Officer Pamela Klein 665 3rd Street,Suite 250 San Francisco CA CALIFORNIA 94107 Executive Officer Pharmaceuticals Decline to Disclose 06b true 0001750284-20-000001 2020-03-13 false true true Series B Preferred stock and Common Stock Issuable upon conversion thereof; Series B Preferred stock issued upon conversion of promissory notes. false 0 55400000 53900000 1500000 (b) includes $3,007,359 attributed to conversion of convertible promissory notes true 0 16 0 0 0 false Olema Pharmaceuticals, Inc. /s/ Cyrus L. Harmon Cyrus L. Harmon CEO 2020-06-18